GSK Stops Antibiotic Trial Early After Positive Results

GSK Plc halted a trial following positive results for an oral antibiotic to treat complicated urinary tract infections that could replace an intravenous medicine that is typically used.

The antibiotic called tebipenem HBr, which is being developed by GSK and Spero Therapeutics, worked as well as an intravenous antibiotic in the late stage trial, the company said Wednesday. GSK plans to file for US approval later this year and will submit the full results to an upcoming scientific congress.